Kidney cancer drug use under the microscope in belgian study
NCT ID NCT04106349
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tracks how 150 patients in Belgium use the drug cabozantinib (Cabometyx), alone or with nivolumab, for advanced or metastatic kidney cancer. It looks at real-world dosing, treatment changes, and quality of life. The goal is to understand how these treatments are actually used outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib (Cabometyx) alone or with nivolumab
What this could lead to
If successful, this study could provide real-world insights into how cabozantinib is used and tolerated in routine care for advanced kidney cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta
Roeselare, 8800, Belgium
-
AZ Glorieux
Ronse, 9600, Belgium
-
AZ Sint-Jan Brugge
Bruges, 8000, Belgium
-
AZ Sint-Lucas
Bruges, 8310, Belgium
-
AZ Turnhout
Turnhout, 2300, Belgium
-
CHC MontLegia
Liège, 4000, Belgium
-
CHR Citadelle Liège
Liège, 4000, Belgium
-
CHR Verviers
Verviers, 4800, Belgium
-
CHU Charleroi - site André Vésale
Montigny-le-Tilleul, 6110, Belgium
-
CHU Liège / Sart-Tilman
Liège, 4000, Belgium
-
CHWAPI
Tournai, 7500, Belgium
-
Clinique Saint-Luc Bouge
Bouge, 5004, Belgium
-
Clinique Saint-Pierre
Ottignies, 1340, Belgium
-
Hôpital Ambroise-Paré Mons
Mons, 7000, Belgium
-
Hôpital de Jolimont
La Louvière, 7100, Belgium
-
Imeldaziekenhuis
Bonheiden, 2820, Belgium
-
Onze-Lieve-vrouw Ziekenhuis Aalst
Aalst, 9300, Belgium
-
UZ Brussel
Brussels, 1090, Belgium
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Ziekenhuis Oost-Limburg Genk
Genk, 3600, Belgium